MiR-145 Regulates the Chemoresistance of Hepatic Carcinoma Cells Against 5-Fluorouracil by Targeting Toll-Like Receptor 4

Rui-Peng Zheng
Dong-Kai Ma
Zhuo Li
Hai-Feng Zhang

Department of Interventional Therapy, The First Hospital of Jilin University, Changchun, Jilin Province 130021, People’s Republic of China; Department of Gastroenterology and Hepatology, Qian Wei Hospital of Jilin Province, Changchun, Jilin Province 130012, People’s Republic of China; Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin Province 130021, People’s Republic of China

Background: 5-fluorouracil (5-FU) is a common drug for hepatic carcinoma (HCC), but the drug resistance of clinical chemotherapy restricts its use. Studies have demonstrated that miRNA molecules can act as a chemoresistance regulator in drug resistance of tumors, whereas the role of miR-145 in the 5-FU-resistant HCC remains unclear.

Objective: To explore the prognostic value of miR-145 in HCC and its molecular mechanism in 5-FU-resistant HCC cells.

Methods: A qRT-PCR assay was conducted to quantify miR-145 in HCC tissues and 5-FU-resistant HCC cells. The Western blot was adopted to analyze the proliferation and apoptosis of 5-FU-resistant HCC cells. The luciferase reporter gene assay showed that TLR4 was the direct target of miR-145, and the Western blot assay revealed that overexpression of TLR4 reversed the inhibitory effect of miR-145 overexpression on proliferation and apoptosis-related proteins.

Results: MiR-145 was expressed lowly in HCC tissues and cells, and linked to high TNM staging and lymph node metastasis of HCC patients. Down-regulation of miR-145 indicated a poorer prognosis and it promoted drug resistance of HCC cells and inhibited cell apoptosis.

Conclusion: MiR-145 is an inhibiting factor in HCC and can target TLR4 to mediate the chemoresistance of HCC, which may provide novel ideas for treating HCC.

Keywords: hepatic carcinoma, miR-145, toll-like receptor 4, TLR4, 5-fluorouracil, drug resistance

Introduction

Hepatic carcinoma (HCC) is a common fatal tumor in human beings, with lethality ranking third. Its treatment is extremely complicated. Although hepatectomy and liver transplantation are relatively effective for HCC, the recurrence rate of patients after them is still terribly high. Clinically, HCC is usually treated with platinum-based chemotherapy or platinum-based chemotherapy combined with radiotherapy. Since the introduction of 5-fluorouracil (5-FU) into the treatment of HCC, the prognosis of patients with HCC has been significantly improved. However, acquired or inherent chemoresistance compromises the efficacy on HCC.
Therefore, we aimed to investigate the molecular mechanism of therapeutic resistance of HCC cells to search for possible therapeutic targets for HCC.

miRNAs are able to change gene expression by specifically binding to an mRNA or protein. They play a key regulatory role in the development and progression of tumor cells, and also take a crucial part in the tumor biosynthesis, growth, and drug resistance. Recent studies have found that miRNA expression can enhance the anti-tumor effect of 5-FU on tumor cells. According to reports, miR-145 acts as a tumor suppressor in various tumors. For example, miR-145 inhibits colorectal cancer tissues and cells and can act as an inhibitor of the DNA damage-related gene RAD18, which plays a crucial role in reversing chemoresistance against 5-FU. In addition, in esophageal squamous cell carcinoma, miR-145 is significantly down-regulated and can directly target the PI3K/AKT pathway to further lower the expression of multidrug resistance-related proteins and enhance the sensitivity to cisplatin. However, the effects of miR-145 on the evolution of chemoresistance of HCC against 5-FU remain unclear.

Toll-like receptors (TLRs) are essential receptors in the body’s immunity, and TLR4 is one of the important members of TLR, which can recognize the lipopolysaccharide of Gram-negative bacteria. TLR4 is widely expressed in tumor tissues and involved in the chemoresistance of tumors. In colorectal cancer cells, TLR4 can be induced by 5-FU and can promote apoptosis under the synergistic effect of lipopolysaccharide and 5-FU. In HCC, TLR4 can result in the poor prognosis of patients after being up-regulated and can be used as a marker of cancer stem cells. In addition, it can promote malignant phenotypes of HCC cells. TLR4 is overexpressed in various tumors including HCC, but its relationship with drug resistance of HCC is still under investigation.

This study focused on the correlation between miR-145 and the resistance of HCC cells against 5-FU to investigate the role of miR-145/TLR4 in chemoresistance of HCC.

Materials and Methods
A total of 102 HCC tissue specimens and corresponding normal paracancerous tissue specimens were sampled from patients undergoing surgery in The First Hospital of Jilin University from March 2011 to June 2014. All the patients were confirmed with HCC and had not received any related treatment before admission, and their expected survival time was longer than one month. This study was carried out with the permission from the ethics committee of the First Hospital of Jilin University and informed consent forms from all participants and it was in accordance with the Helsinki Declaration.

Cell Source and Culture
HCC cells (SNU449 and Huh7) and normal hepatic cell strains (LO2) purchased from Shanghai Xin Yu Biotech Co., Ltd. were cultured in RPMI 1640 medium (Gibco Company, USA) containing 50 U/mL penicillin, 50 μg/mL streptomycin, as well as 10% fetal bovine serum (FBS) under 5% CO2 at 37°C. After 22–25 passages, the SNU449 and Huh7 cells were incubated in RPMI 1640 with 2.0 μg/mL 5-FU (Sigma-Aldrich, USA) that was replaced each day to make the cells resistant to 5-FU, thus establishing SNU449/5-FU and Huh7/5-FU cells.

Cell Transfection
MiR-145 overexpression sequence (miR-145-mimics), miR-145 knockout sequence (miR-145-inhibitor) and corresponding miR negative control (miR-NC) were purchased from MBL Beijing Biotech Co., Ltd. (China). The full-length TLR4 sequence was introduced into pcDNA3.1 vector (Zeye Biological Technology Co., Ltd., Shanghai, China) to obtain overexpressed TLR4 (TLR4-pcDNA3.1), and blank vector was adopted as control (TLR4-NC). After the cell confluency reached 70%-80%, the cell plasmids were transfected with Lipofectamine 2000 reagent (Huijia Biotechnology Co., Ltd., Xiamen, China) under manufacturer’s instructions, and the final concentration of miRNA was 50nM. Finally, a qRT-PCR assay was carried out to determine the transfection efficiency of cells, and the assay was repeated three times.

qRT-PCR
Total RNA was extracted from cells through TRizol reagent (Huijia Biotechnology Co., Ltd., Xiamen, China) under manufacturer’s instructions, and its purity and concentration were detected by a Multiskan Sky ultraviolet spectrophotometer (Thermo Fisher Scientific, Shanghai, China). The integrity of extracted total RNA was determined using the agarose gel electrophoresis. In addition, the extracted RNA was reversely transcribed using a reverse transcription kit. The reaction solution consisted of 4 μL 5 ×PrimeScript Buffer, RNase Inhibitor (40U/μL), 1 μL PrimeScript RTase (200U/μL), and 4.5 μL RNase-free ddH2O. Reverse transcription reaction was carried out under reaction at 42°C for 45 min, incubation at 95°C for
5 min, and cooling on ice, and then the generated cDNA was stored at −20°C. The amplification experiment was carried out using PrimeScript RT Master Mix reagent (Applied Biosystems Company, USA) on an ABI 7500 fluorescence ration PCR instrument (Thermo Fisher Scientific, Shanghai, China) with pre-denaturation at 95°C for 5 min, followed by denaturation at 95°C for 30 min, annealing at 60°C for 30 s, and extension at 72°C for 30 s. With U6 or GAPDH as internal reference, the obtained data were analyzed using 2-ΔΔCt, and the assay was repeated three times.

**Cell Viability Determination**

Cell viability was detected using a CCK-8 Kit (Sigma-Aldrich, USA) as follows: The cells were seeded into a 96-well plate at 2×10^4 cells/well, and cultured at 37°C. After 24 hrs of transfection, the cells were added with 5-FU at different concentrations, and after 48 hrs of culturing, the optical density of cells at 450 nm was determined using a Multiskan microplate reader (Thermo Fisher Scientific, Shanghai, China).

**Determination of Apoptosis and Cell Cycle**

The cells were seeded into a 6-well plate at 2×10^5 cells/well, and cultured until their confluence reached 90%, followed by later analysis. Subsequently, the cells were cultured with 5 μg/mL 5-FU for 48 hrs, and then their apoptosis was determined via Annexin V-FITC Kit (Huijia Biotechnology Co., Ltd., Xiamen, China) under the kit instructions. The treated cells were prepared into 1×10^6 cells/mL cell suspension, followed by incubation with Annexin V-FITC and propidium iodide in the dark. Finally, the cells were determined using a CyFlow Cubex flow cytometer (Jiyuan Biotechnology Co., Ltd., Guangzhou, China).

**Western Blot (WB) Assay**

The cells were lysed through RIPA solution (Thermo Scientific, USA), and their concentration was determined using a Bicinchoninic Acid Kit (Bio-Rad, USA), and regulated to 4 μg/μL. Subsequently, the total protein was separated through SDS-PAGE and transferred to a PVDF membrane. The membrane was immersed in 5% skimmed milk for 2 h and added with TLR4, myeloid differentiation factor 88 (MyD88), cysteinyl aspartate specific proteinase 3 (Caspase3), Caspase9, B-cell lymphoma/leukemia-2 (Bcl-2), and Bcl-2-associated X protein (Bax) primary antibody, at a dilute ratio of 1:1000 each, and cultured at 4°C overnight, with GAPDH (1:1000) as internal control. Afterwards, the cells were reacted with secondary antibody (1:5000) at room temperature for 2 hrs. The protein was visualized with electrochemiluminescence (ECL) reagent and the band was quantitatively analyzed with ImageJ. Antibody reagents were all purchased from Shanghai Beyotime Biotechnology Co., Ltd. (China).

**Luciferase Determination**

Based on Targetscan7.2 and miRDB database, it was predicted that TLR4 might be a target of miR-145. Wild type (WT) TLR4 and mutant (Mut) TLR4 were cloned into pmirGLO dual luciferase expression vector, and sequenced downstream of luciferase reporter gene. Subsequently, TLR4-WT or TLR4-MUT was co-transfected with miR-145-mimics or miR-NC into SNU449 cells using Lipofectamine 2000 reagent. Finally, the luciferase activity of cells was determined with a dual-luciferase reporter (DLR) assay system (Yingbio Technology Co., Ltd., Shanghai, China) in accordance with the manufacturer’s instructions.

**In vitro Xenotransplantation**

Lentivirus-mediated stably expressed miR-145 and miR-NC were purchased from Shanghai Gene Pharma Co., Ltd. (China). Cells were placed in a culture medium, and when their density reached 50%, they were incubated in complete medium supplemented with 1 mL lentivirus solution and 15 μg polybrene. After 48 h of cell transfection, stably transfected cell strains were screened using complete culture solution with 2 μg/mL puromycin. BALB/c nude mice (5-week-old) were purchased from Changzhou Cavens Experimental Animal Co., Ltd. (China), and 1×10^6 HCC cells with stable miR-NC, miR-145 mimics, miR-NC+5-FU, or miR-145 mimics+5-FU were suspended in PBS solution, and 0.2 mL suspension cells were injected subcutaneously into nude mice. Eight days after continuous feeding, the tumor in each mouse was measured every 4 days. After 24 days, the nude mice were euthanized, and their tumor tissues were taken out and the tissue mass was detected.

All the experiments involving animals in the study were carried out with approval from the Animal Ethics Committee of the First Hospital of Jilin University and carried out under the guidance of the Animal Ethics Committee and in line with the institutional ethics guidelines for animal experiments.
Statistical Analyses
Data in experiments were expressed as the mean ± standard deviation (mean ± SD), compared between groups using the t test, and compared among groups using the one-way variance. Post hoc pairwise comparison of data was carried out using the Bonferroni method. The Kaplan-Meier method was adopted to draw survival curves of HCC patients, and the Log rank test was adopted for analysis of the survival curves. Furthermore, Cox model was used to analyze the prognostic factors, and Pearson correlation coefficient was adopted for correlation analysis. Enumeration data were expressed by %, and compared between groups using the chi-square test. P<0.05 indicates a significant difference. Statistical analyses and figure drawing were carried out using SPSS 17.0 and GraphPad 6, respectively.

Results
MiR-145 is Lowly Expressed in Cases with HCC and the Low Expression Indicates Poor Prognosis of Patients
First, we carried out a qRT-PCR assay to quantify miR-145 in HCC tissues, finding that miR-145 was significantly down-regulated (Figure 1). We further analyzed the relationship between miR-145 and pathological parameters of HCC patients, finding that low miR-145 expression was linked to high TNM staging and the existence of lymph node metastasis. Additionally, we analyzed the relationship between miR-145 and patients’ 5-year overall survival (OS) by defining high and low miR-145 expression according to the median miR-145 expression in tissues (1.26) and found that patients with low miR-145 expression showed poorer 5-year OS. Cox regression analysis revealed that lymph node metastasis, TNM staging, and low miR-145 expression were independent prognostic indicators of patients’ 5-year OS (Figure 1, Table 1–2).

MiR-145 is Lowly Expressed in 5-FU-Resistant HCC Cells
We acquired that miR-145 was lowly expressed in HCC cells (SNU449 and Huh7), and then we constructed SNU449/5-FU cell strains and Huh7/5-FU cell strains. It was found that after 5-FU treatment, SNU449/5-FU cell strains and Huh7/5-FU cell strains showed significantly stronger proliferation and significantly weaker apoptosis.
than SNU449 and Huh7 cells. Quantification of miR-145 in drug-resistant cell strains and parental cell strains revealed that SNU449/5-FU cell strains and Huh7/5-FU cell strains showed significantly lower miR-145 expression than SNU449 and Huh7 cells. These results imply that miR-145 plays a role in the progression of HCC and drug resistance of it (Figure 2).

### MiR-145 Plays a Role in Drug Resistance of HCC Cells

In order to verify the effect of miR-145 on resistance of HCC cells against 5-FU, we transfected miR-145 mimics, miR-145 inhibitor, and corresponding miR-NC into drug-resistant cell strains and parental cell strains. It was turned out that compared with the transfection of miR-NC, transfection of miR-145 mimics significantly up-regulated miR-145 in drug-resistant cell strains and parental cell strains, while transfection of miR-145 inhibitor exerted opposite effects. The CCK-8 assay revealed that compared with transfection of miR-NC, knock-down of miR-145 promoted the growth of SNU449 cells and SNU449/5-FU cells and inhibited their apoptosis, while up-regulation of miR-145 inhibited the growth of Huh7 cells and Huh7/5-FU cells and induced their apoptosis, which implied that

### Table 1 Relationship Between MiR-145 Expression and Clinicopathological Features of HCC Patients

| Clinicopathological Parameters       | n    | MiR-145 Low Expression | MiR-145 High Expression | \( \chi^2 \) | P-value |
|--------------------------------------|------|------------------------|-------------------------|-------------|---------|
| Age (Y)                              |      |                        |                         |             |         |
| <60                                  | 59   | 28 (54.90)             | 31 (60.78)              | 0.362       | 0.548   |
| ≥60                                  | 43   | 23 (45.10)             | 20 (39.22)              |             |         |
| Sex                                  |      |                        |                         |             |         |
| Female                               | 27   | 11 (21.57)             | 16 (31.37)              | 1.259       | 0.262   |
| Male                                 | 75   | 40 (78.43)             | 35 (68.63)              |             |         |
| TNM staging                          |      |                        |                         |             |         |
| I–II                                 | 58   | 23 (45.10)             | 35 (68.63)              | 5.755       | 0.016   |
| III–IV                               | 44   | 28 (54.90)             | 16 (31.37)              |             |         |
| Histological grading                 |      |                        |                         |             |         |
| G1/G2                                | 60   | 28 (54.90)             | 32 (62.75)              | 0.648       | 0.421   |
| G3                                   | 42   | 23 (45.10)             | 19 (37.25)              |             |         |
| Lymph node metastasis                |      |                        |                         |             |         |
| No                                   | 59   | 24 (47.06)             | 35 (68.63)              | 4.865       | 0.027   |
| Yes                                  | 43   | 27 (52.94)             | 16 (31.37)              |             |         |
| Tumor size                           |      |                        |                         |             |         |
| <5cm                                 | 68   | 33 (64.71)             | 35 (68.63)              | 0.177       | 0.674   |
| ≥5cm                                 | 34   | 18 (35.29)             | 16 (31.37)              |             |         |

**Abbreviations:** miR, microRNA; HCC, hepatic carcinoma; TNM, tumor node metastasis.

### Table 2 Univariate and Multivariate Regression Analyses of Relevant Prognostic Parameters of HCC Patients

| Factors                  | Univariate | Multivariate |
|--------------------------|------------|--------------|
|                         | HR (95%CI) | P-value      | HR (95%CI) | P-value |
| Age (Y)                 | 1.060 (0.683–1.645) | 0.795 | 1.612 (1.040–2.499) | 0.033 |
| Sex                     | 1.236 (0.746–2.048)  | 0.410 | 1.774 (1.131–2.783) | 0.013 |
| TNM staging             | 1.647 (1.063–2.553)  | 0.026 | 1.574 (1.004–2.469) | 0.048 |
| Histological grading    | 1.103 (0.709–1.714)  | 0.664 |          |         |
| Lymph node metastasis   | 1.939 (1.244–3.022)  | 0.003 |          |         |
| Tumor size              | 1.390 (0.886–2.182)  | 0.152 |          |         |
| miR-145                 | 1.755 (1.127–2.734)  | 0.013 |          |         |

**Abbreviations:** HCC, hepatic carcinoma; HR, hazard ratio; CI, confidence interval; TNM, tumor node metastasis; miR, microRNA.
miR-145 plays a crucial role in regulating the sensitivity and drug resistance to 5-FU. In order to evaluate the effect of miR-145 on drug resistance against 5-FU in vivo, we carried out an in vitro nude mouse formation assay by injecting SNU449/5-FU cells with stably expressed miR-145 into nude mice. As expected, miR-145 overexpression significantly inhibited tumor growth, and it also enhanced the sensitivity to 5-FU. These studies imply that miR-145 can make HCC cells sensitive to 5-FU in vivo (Figure 3).

**TLR4 is a Direct Target of MiR-145 in HCC**

For the purpose of studying the role of miR-145 in regulating the sensitivity of drug-resistant HCC cells to 5-FU, we carried out an analysis according to the public database (TargetScan), finding that TLR4 was a target gene of miR-145. Then, we carried out a DLR assay, finding that miR-145 mimics inhibited the luciferase activity of WT-TLR4 3'UTR by binding to its 3'UTR, but exerted no effect on that of MUT-TLR4. We further quantified TLR4 in cells. The WB assay revealed that knock-down of miR-145 up-regulated TLR4 in SNU449 cells and SNU449/5-FU cells, while overexpression of miR-145 down-regulated TLR4 in Huh7 and Huh7/5-FU cells. Consistently, HCC cells showed higher TLR4 expression than normal tissues. Furthermore, miR-145 was negatively correlated with TLR4 expression in HCC cells (Figure 4).

**TLR4 is a Functional Target of MiR-145 in Drug-Resistant HCC Cells**

In order to verify the effects of TLR4 on miR-145-mediated chemical resistance, we transfected miR-NC, miR-145 mimics, miR-NC+TLR4-NC, and miR-145 mimics into drug-resistant HCC cells. The DLR assay revealed that TLR4 overexpression could overcome the resistance induced by miR-145 mimics, while TLR4 knock-down could enhance the sensitivity to 5-FU in drug-resistant HCC cells (Figure 5).
mimics+TLR4-pcDNA3.1 into SNU449/5-FU cells and Huh7/5-FU cells, finding that overexpression of TLR4 enhanced the cell proliferation ability caused by miR-145 overexpression and lowered the apoptosis rate caused by it. In addition, WB assay revealed that up-regulation of TLR4 reversed the inhibitory effect of miR-145 overexpression on TLR4 and MyD88 proteins, and quantification of apoptosis-related proteins revealed that miR-145 overexpression increased the expression of Caspase3, Caspase9, and Bax and lowered Bcl-2 expression, while up-regulation of TLR4 reversed the effect of miR-145 overexpression on the apoptosis-related proteins. Additionally, overexpression of TLR4 prevented the inhibition of the up-regulation of miR-145 on drug-resistant HCC cells, which indicated that the action of miR-145 on drug resistance of HCC cells may depend on TLR4 (Figure 5).

**Discussion**

Growing studies show that miRNA plays a crucial role in malignant tumors and may be important for the development, prognosis, and treatment of cancer. In this study, the loss of miR-145 expression was linked to the progression of HCC, and low miR-145 expression indicated an unfavorable prognosis of patients. In addition, miR-145 expression in drug-resistant HCC cells decreased, and importantly, overexpression of miR-145 could suppress the proliferation of drug-resistant HCC cells and promoted their apoptosis. Our in vivo experiments verified that up-regulation of miR-145 could strongly hinder the growth of...
tumors and enhance the sensitivity to 5-FU, and rescue experiments revealed that up-regulation of TLR4 could prevent overexpression of miR-145 from sensitizing drug-resistant HCC cells, which suggested that the action of miR-145 on drug resistance of HCC cells may depend on TLR4. Our study confirmed for the first time that the function of miR-145 in chemoresistance of HCC against 5-FU.

One previous study has demonstrated that the functional status of miRNA is strongly linked to the response of cancer patients to chemotherapy. Although the mechanism of miRNA resistance is still under investigation, there are evidence indicating that miRNA plays a pivotal role in treatment-induced tumor cell death, changes in drug targets, and regulation of multidrug resistance-related proteins. According to earlier studies, miR-145 mostly acts as a tumor suppressor in malignant tumors. Our study results demonstrated that miR-145 was lowly expressed in HCC, and was linked to high clinical staging and lymph node metastasis. In addition, follow-up for prognosis revealed that low miR-145 expression was linked to the unfavorable prognosis of the patients. Consistently, miR-145 has been reported to be lowly expressed in HCC tissues and cells. For instance, Liu et al have pointed out that up-regulation of miR-145 can inhibit the malignant phenotypes of cells in vitro experiments, and can target ROCK1 to further inhibit the metastasis and progression of HCC. It is worth noting that in one study by Noh et al, miR-145 expression in HCC cells is significantly down-regulated, and up-regulation of miR-145 can degrade the growth of HCC cells and directly target histone deacetylase 2 to further suppress tumor. In our study, we found that knockdown of miR-145 could enhance the proliferation of drug-resistant HCC cells and inhibit their apoptosis, and over-expression of miR-145 could restore the apoptosis of 5-FU-resistant cells and inhibit their proliferation. In addition, according to the in vivo experiments, the up-regulation of

---

**Figure 4** TLR4 is a direct target of miR-145 in HCC. (A) There were targeted binding sites between miR-145 and TLR4. (B) Interaction between miR-145 and TLR4 according to the DLR assay. (C) Expression of TLR4 protein in cells transfected with miR-145-mimics, miR-145-inhibitor or corresponding miR-NC according to the WB assay, and protein bands. (D) Expression of TLR4 protein in HCC tissues and corresponding paracancerous tissues according to the qRT-PCR assay. (E) Expression of TLR4 protein in HCC tissues and corresponding paracancerous tissues according to the WB assay, and protein bands. (F) Negative correlation between miR-145 and TLR4 in HCC tissues.

**Notes:** **Indicates P<0.01, and ***Indicates P<0.001.

**Abbreviations:** TLR4, toll-like receptor 4; miR, microRNA; WT, wild type; MUT, mutant type; 5-FU, 5-fluourouracil.
miR-145 could make HCC cells sensitive to 5-FU. These results imply that miR-145 plays a key role in regulating the sensitivity and resistance of cells to 5-FU and up-regulation of miR-145 can enhance the anti-tumor effect of 5-FU on HCC cells. However, the mechanism of miR-145 in 5-FU-resistant HCC cells is still under investigation.

The latest studies have concluded that the functions of miRNA and their targets are crucial to the development or chemical resistance of tumors. For example, in gallbladder carcinoma, up-regulation of miR-145 can improve the therapeutic effect of cisplatin, whereas down-regulation of it can lower the sensitivity to the drug, and can directly target multidrug resistance-related protein 1 in gallbladder cancer cells to cause cisplatin toxicity increase. Furthermore, one other study has revealed that miR-145 overexpression in drug-resistant ovarian cancer cells can reduce the expression of pRb and P-gp, making cells more sensitive to paclitaxel in vivo or in vitro experiments. Therefore, we carried out bioinformatics analysis and found potential binding sites between miR-145 and TLR4, and we also carried out a DLR assay, and confirmed that TLR4 was the target of miR-145. TLR4 is overexpressed in human tumors and is strongly linked to metastasis and chemical resistance. According to previous reports, in breast cancer, TLR4 promotes the tumor development, and activation of TLR4 pathway can improve the survival rate of tumor cells, while blocking TLR4 can improve the therapeutic effect of paclitaxel on breast cancer cells. However, there is no relevant research on the relationship between TLR4 and 5-FU resistance in HCC cells. Through detection, we found that TLR4 was overexpressed in HCC tissues. Consistently, TLR4 was expressed at high levels in patients with HCC, and the increase of its level indicates the early recurrence and poor survival rate of patients. Our study results further demonstrated that up-regulation

**Figure 5** TLR4 is a functional target of miR-145 in drug-resistant HCC cells. (A) Proliferation ability of SNU449/5-FU cells and Huh7/5-FU cells according to the CCK-8 assay. (B) Apoptosis rate of SNU449/5-FU cells and Huh7/5-FU cells according to the flow cytometry and apoptosis map. (C) Expression of TLR4 and MyD88 proteins according to the WB assay and protein bands. (D) Expression of Caspase3, Caspase9, Bcl-2, and Bax proteins according to the WB assay and protein bands.

**Notes:** *Indicates $P<0.05$; and ***indicates $P<0.001$.

**Abbreviations:** miR, microRNA; TLR4, toll-like receptor 4; 5-FU, 5-fluorouracil; MyD88, myeloid differentiation factor 88; Caspase3, cysteinyl aspartate specific proteinase 3; Caspase9, cysteinyl aspartate specific proteinase 9; Bcl-2, B-cell lymphoma/leukemia-2; Bax, Bcl-2-associated X protein.
of miR-145 could intensify the therapeutic sensitivity of 5-Fu-resistant HCC, and transfection of overexpressed miR-145 and overexpressed TLR4 into 5-Fu-resistant HCC cells could offset the sensitizing effect of miR-145 overexpression on 5-Fu-resistant cells, which implied that miR-145 acted as a tumor suppressor gene in HCC, and up-regulation of it can increase the sensitivity of 5-Fu-resistant HCC cells. We further investigated the effects of miR-145 on the drug resistance of HCC. The WB assay revealed that the up-regulation of TLR4 reversed the inhibitory action of miR-145 overexpression on TLR4 and MyD88 proteins, and could reverse the levels of apoptosis-related proteins. Silencing the TLR4 signaling pathway in cancer cells can reduce the risk of tumor formation.

Previous studies have shown that TLR4-mediated signaling pathway takes a crucial part in malignant phenotypes of HCC cells, and knocking out TLR4 can suppress cell proliferation and promote cell apoptosis, and inhibit TLR4 pathway, which indicates that miR-145 may regulate the sensitivity of drug-resistant human HCC cells by mediating the TLR4/MyD88 pathway. However, we have not detected other factors related to the TLR4 signaling pathway, and the specific mechanism of action in the signaling pathway mediated downstream of TLR4 mediated by miR-145 is unclear. In addition, the effects of miR-145 on drug-resistant HCC cells still need further exploration.

Conclusion

MiR-145 may be adopted as a prognostic marker for HCC, and up-regulation of it can enhance the anti-tumor effect of 5-Fu on HCC cells, which may be achieved by mediating the chemical resistance of HCC by targeting TLR4.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Pepe F, Pagotto S, Soliman S, et al. Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells. Oncogenesis. 2017;6(5): e328. doi:10.1038/oncogenesis.2017.35
2. Sandbothe M, Buurman R, Reich N, et al. The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 2017;66(5):1012–1021. doi:10.1016/j.jhep.2017.01.004
3. Ji DG, Guan LY, Luo X, Ma F, Yang B, Liu HY. Inhibition of MALAT1 sensitizes liver cancer cells to 5-fluorouracil by regulating apoptosis through IKKalpha/NF-kappaB pathway. Biochem Biophys Res Commun. 2018;501(1):33–40. doi:10.1016/j.bbrc.2018.04.116
4. Fu C, Wang L, Tian G, et al. Enhanced anticancer effect of oncostatin M combined with salinomycin in CD133(+) HepG2 liver cancer cells. Oncol Lett. 2019;17(2):1798–1806. doi:10.3892/ol.2018.9796
5. Jiang L, Wang H, Chen S. Aptamer (AS1411)-conjugated liposome for enhanced therapeutic efficacy of miRNA-29b in ovarian cancer. J Nanosci Nanotechnol. 2020;20(4):2025–2031. doi:10.1166/jnn.2020.173001
6. Xu F, Ye ML, Zhang YP, et al. MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Cancer Sci. 2020;111(5):1528–1541. doi:10.1111/cas.14356
7. Wang W, Liu B, Sun S, et al. Downregulation of miR-486-5p enhances the anti-tumor effect of 5-fluorouracil on pancreatic cancer cells. Onco Targets Ther. 2020;13:1649–1659. doi:10.2147/OTT.S231153
8. Misono S, Seki N, Mizuno K, et al. Dual strands of the miR-145 duplex (miR-145-5p and miR-145-3p) regulate oncogenes in lung adenocarcinoma pathogenesis. J Hum Genet. 2018;63(10):1015–1028. doi:10.1038/s10038-018-0497-9
9. Liu RL, Dong Y, Deng YZ, Wang WJ, Li WD. Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer. Tumour Biol. 2015;36(7):5011–5019. doi:10.1007/s13277-015-3152-5
10. Zheng TL, Li DP, He ZF, Zhao S. miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int. 2019;19(1):250. doi:10.1186/s12955-019-0943-6
11. Skjøsdal A, Yurchenko M, Bosl K, et al. The TLR4 adaptor TRAM controls the phagocytosis of Gram-negative bacteria by interacting with the Rabi11-family interacting protein 2. Plos Pathog. 2019;15(3):e1007684. doi:10.1371/journal.ppat.1007684
12. Sun NK, Huang SL, Chang TC, Chao CC. TLR4 and NFKappaB signaling is critical for taxol resistance in ovarian carcinoma cells. J Cell Physiol. 2018;233(3):2489–2501. doi:10.1002/jcp.26125
13. de Almeida Chuffa LG, de Moura Ferreira G, Lupi LA, da Silva Nunes I, Favaro WJ. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling. J Ovarian Res. 2018;11(1):8. doi:10.1186/s13048-018-0380-5
14. Davoodi H, Hashemi SR, Seow HF. 5-Fluorouracil induces the expression of TLR4 on HCT116 colorectal cancer cell line expressing different variants of TLR4. Iran J Pharm Res. 2013;12(2):435–460.
15. Yin Y, Li F, Li S, Cai J, Shi J, Jiang Y. TLR4 influences hepatitis B virus related hepatocellular carcinoma by regulating the wnt/beta-catenin pathway. Cell Physiol Biochem. 2017;42(2):469–479. doi:10.1159/000475594
16. Bhatia S, Miller NJ, Lu H, et al. Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with mirel cell carcinoma. Clin Cancer Res. 2019;25(4):1185–1195. doi:10.1158/1078-0432.CCR-18-0469
17. Jiang K, Al-Diffahla S, Centeno BA. Primary liver cancers-part 1: histopathology, differential diagnoses, and risk stratification. Cancer Control. 2018;25(1):1073274817744625. doi:10.1177/1073274817744625
18. Nagy A, Lancezy A, Menhart O, Gryfford B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y
19. Mansoori B, Mohammadi A, Ghasabi M, et al. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. J Cell Physiol. 2019;234(6):9816–9825. doi:10.1002/jcp.27670
20. Korourian A, Roudi R, Sharifatbazi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242(18):1842–1847. doi:10.1177/15353702177278460
21. Chakraborty C, Sharma AR, Sharma G, Sarkar BK, Lee SS. The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. *Oncotarget*. 2018;9(11):10164–10174. doi:10.18632/oncotarget.24309

22. Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. *Int J Cancer*. 2017;141(2):220–230. doi:10.1002/ijc.30669

23. Yu G, Jia B, Cheng Y, et al. MicroRNA-429 sensitizes pancreatic cancer cells to gemcitabine through regulation of PDCD4. *Am J Transl Res*. 2017;9(11):5048–5055.

24. Zeng JF, Ma XQ, Wang LP, Wang W. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. *World J Gastroenterol*. 2017;23(13):2337–2345. doi:10.3748/wjg.v23.i13.2337

25. Sheng Q, Zhang Y, Wang Z, Ding J, Song Y, Zhao W. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. *Clin Exp Immunol*. 2020;200(1):45–52. doi:10.1111/cei.13406

26. Liang H, Sun H, Yang J, Yi C. miR1455p reduces proliferation and migration of hepatocellular carcinoma by targeting KL5. *Mol Med Rep*. 2018;17(6):8332–8338. doi:10.3892/mmr.2018.8880

27. Liu Y, Wu C, Wang Y, et al. MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. *Oncol Rep*. 2014;32(5):1923–1930. doi:10.3892/or.2014.3424

28. Noh JH, Chang YG, Kim MG, et al. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. *Cancer Lett*. 2013;335(2):455–462. doi:10.1016/j.canlet.2013.03.003

29. Kong J, Qiu Y, Li Y, Zhang H, Wang W. TGF-beta1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis. *Biopharm Drug Dispos*. 2019;40(2):70–80. doi:10.1002/bdd.2172

30. Shang M, Wang X, Zhang Y, Gao Z, Wang T, Liu R. LinRNA-ROR promotes metastasis and invasion of esophageal squamous cell carcinoma by regulating miR-145/FSCN1. *Onco Targets Ther*. 2018;11:639–649. doi:10.2147/OTT.S157638

31. Zhan M, Zhao X, Wang H, et al. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. *Tumour Biol*. 2016;37(8):10553–10562. doi:10.1007/s12777-016-4957-6

32. Zhu X, Li Y, Xie C, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. *Int J Cancer*. 2014;135(6):1286–1296. doi:10.1002/ijc.28774

33. Wanderley CW, Colon DF, Luiz JPM, et al. Paclitaxel Reduces Tumor Growth by Reprogramming Tumor-Associated Macrophages to an M1 Profile in a TLR4-Dependent Manner. *Cancer Res*. 2018;78(20):5891–5900. doi:10.1158/0008-5472.CAN-17-3480

34. Raiput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. *Mol Cancer Ther*. 2013;12(8):1676–1687. doi:10.1158/1535-7163.MCT-12-1019

35. Liu WT, Jing YY, Yu GF, et al. Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma. *Cancer Lett*. 2015;358(2):136–143. doi:10.1016/j.canlet.2014.12.019

36. Yao RR, Li JH, Zhang R, Chen RX, Wang YH. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. *World J Surg Oncol*. 2018;16(1):9. doi:10.1186/s12957-018-1312-y

37. Liu Y, Li T, Xu Y, et al. Effects of TLR4 gene silencing on the proliferation and apoptosis of hepatocarcinoma HepG2 cells. *Oncol Lett*. 2016;11(5):3054–3060. doi:10.3892/ol.2016.4338